Navigation Links
Life Science Labs Reacting to the Economic Crisis
Date:2/11/2009

ARLINGTON, Va., Feb. 11 /PRNewswire/ -- Scientists engaged in biological research and drug discovery are bracing for expected cuts in their 2009 lab budgets. BioInformatics, LLC (www.gene2drug.com), the premier research and advisory firm serving the life science market, has released preliminary data from the company's newest report Prospering in a Down Market: Strategies for Life Science Suppliers.

In this report, we set out to understand current sources of funding for research and drug discovery and what effect the current economic situation will have on each," says Tamara Zemlo, Ph.D., Vice President of Advisory Services. "Our clients need to know scientists' level of concern over the economic crisis and how this may impact anticipated purchases in 14 product categories."

In response to requests from the life science supply industry, BioInformatics, LLC fielded a detailed 45-question survey to more than 500 senior scientists and lab managers working in universities, and pharmaceutical and biotechnology companies. The final results will be published in early March.

Nearly half of respondents surveyed said they are VERY worried that a recession will make it difficult for them to conduct their research and close to two-thirds indicated that their research has already been affected by the current economic recession. According to Zemlo, life sciences will likely fare better than other sectors of the economy but she points out that scientists are employing a variety of ways to stretch their budgets. "Understanding how and where scientists intend to cut back will be essential for suppliers developing effective marketing and sales strategies."

A complimentary pre-publication Executive Summary of the report is available at http://www.gene2drug.com/reports/default.asp?action=details&report_id=200

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 40,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:
    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13(phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... IA (PRWEB) , ... March 01, 2017 , ... ... announce finalization of an agreement that formalizes their clinical research partnership. Effective ... McFarland Clinic. This collaboration brings an increased opportunity for McFarland Clinic patients and ...
(Date:3/1/2017)... March 1, 2017  Elizabeth Young and Joshua ... the George Washington University,s Health Workforce Speaker series. ... Rosenthal will be speaking on March 9, 2017 ... Washington, DC at 12:00pm. ... invites nationally renowned speakers to examine new workforce configurations, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... Inc. (Newark, DE) have formed a strategic partnership to develop and market ... renewable energy laboratories. These automated testing solutions will save analysis time and ...
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):